Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
NANJING, China, Nov. 1, 2012 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2012 on Thursday, November 15, 2012, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 15, at 9 p.m. Beijing/Hong Kong time).
To access the conference call, please dial:
| International toll: |
+65.6723.9381 |
| United States toll-free: |
+1.866.519.4004 |
| United States toll: |
+1.718.354.1231 |
| China Domestic toll: |
800.819.0121 |
| China Domestic mobile toll: |
400.620.8038 |
| Hong Kong toll: |
+852.2475.0994 |
Please ask to be connected to Q3 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 57347315.
Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.
Following the earnings conference call, an archive of the call will be available by dialing:
| United States toll-free: |
+1.866.214.5335 |
| United States toll: |
+1.718.354.1232 |
The passcode for replay participants is 57347315. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
| Investor and Media Contacts: |
|
| Email: [email protected] |
|
| In Nanjing: Jie Liu D'Elia Vice President Simcere Pharmaceutical Group Tel: 86-25-8556-6666*8857
In Beijing: Yue Yu Brunswick Group Tel: 86-10-5960-8600 |
In the United States: Carly Westerman Brunswick Group Tel: 1-212-333-3810
Joseph Lo Chi-Lun Brunswick Group Tel: 852-3512-5000 |
SOURCE Simcere Pharmaceutical Group
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article